Table 2.
Antimicrobial susceptibility tests for P. mirabilis strains used in this study (n = 30).
| Antimicrobial drug | Abbreviation | Breakpoint (μg/ml) | Results (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Species | Name | S | I | R | S | I | R | |
| Tetracyclines | ||||||||
| Tetracycline | TET | ≤4 | 8 | ≥16 | 0% (0/30) | 0% (0/30) | 100.00% (30/30) | |
| Minocycline | MIN | ≤4 | 8 | ≥16 | 0% (0/30) | 0% (0/30) | 100.00% (30/30) | |
| Fluoroquinolones | ||||||||
| Ofloxacin | OFX | ≤2 | 4 | ≥8 | 30.00% (9/30) | 26.67% (8/30) | 43.33% (13/30) | |
| Naphthaleneic acid | NAL | ≤16 | – | ≥32 | 26.67% (8/30) | 0% (0/30) | 73.33% (22/30) | |
| Ciprofloxacin | CIP | ≤0.25 | 0.5 | ≥1 | 23.33% (7/30) | 0% (0/30) | 76.67% (23/30) | |
| Macrolide | ||||||||
| Azithromycin | AZ | ≤2 | 4 | ≥8 | 0% (0/30) | 0% (0/30) | 100.00% (30/30) | |
| Erythromycin | EM | ≤0.5 | 1 | ≥8 | 0% (0/30) | 0% (0/30) | 100.00% (30/30) | |
| β-Lactam combinations | ||||||||
| Ampicillin | AMP | ≤8 | – | ≥16 | 10.00% (3/30) | 0% (0/30) | 90.00% (27/30) | |
| Amoxicillin/clavulanic acid | AMC | ≤8/4 | – | ≥16/8 | 10.00% (3/30) | 0% (0/30) | 90.00% (27/30) | |
| Ceftiofur | CEF | ≤2 | 4 | ≥8 | 16.67% (5/30) | 6.67% (2/30) | 76.67% (23/30) | |
| Meropenem | MEM | ≤1 | 2 | ≥4 | 40.00% (12/30) | 60.00% (18/30) | 0% (0/30) | |
| Aminoglycosides | ||||||||
| Amikacin | AMK | ≤16 | 32 | ≥64 | 70.00% (21/30) | 10.00% (3/30) | 20.00% (6/30) | |
| Gentamicin | GEN | ≤4 | 8 | ≥16 | 30.00% (9/30) | 13.33% (4/30) | 56.67% (17/30) | |
| Phenicols | ||||||||
| Chloramphenicol | CHL | ≤8 | 16 | ≥32 | 0% (0/30) | 0% (0/30) | 100.00% (30/30) | |
| Rifamycin | ||||||||
| Rifamycin | RIF | ≤1 | 2 | ≥4 | 26.67% (8/30) | 33.33% (10/30) | 40.00% (12/30) | |